Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Moodys
Cerilliant
Johnson and Johnson
Cantor Fitzgerald
Deloitte
Julphar
Queensland Health
Daiichi Sankyo

Generated: May 26, 2018

DrugPatentWatch Database Preview

PAXIL CR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Paxil Cr patents expire, and what generic alternatives are available?

Paxil Cr is a drug marketed by Apotex Technologies and is included in one NDA.

The generic ingredient in PAXIL CR is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.
Drug patent expirations by year for PAXIL CR
Pharmacology for PAXIL CR
Synonyms for PAXIL CR
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine
(-)-Paroxetine
(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine
(-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine
(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine
(3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
[3H]Paroxetine
110429-35-1
110429-35-1 (HCl hemihydrate)
3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride
3h-paroxetine
41VRH5220H
61869-08-7
63952-24-9
64006-44-6 (maleate)
72471-80-8 (acetate)
78246-49-8 (hydrochloride)
869P087
8PR
AB00053704_22
AB00053704_23
AB00053704-21
AB00514724
AC-8185
AC1L2AKL
AC1Q1H18
AC1Q4LV6
AHOUBRCZNHFOSL-YOEHRIQHSA-N
AJ-23329
AK501459
AKOS015888636
AN-8247
Aropax
BDBM22416
BDBM50331515
BIDD:GT0673
BPBio1_000949
BRD-K37991163-003-02-7
Brisdelle
BRL 29060
BRL-29060
BRL-29060A
BSPBio_000861
C-19975
C07415
C19H20FNO3
CAS-61869-08-7
Casbol
CC-33477
CHEBI:7936
CHEMBL1708
CHEMBL490
D02362
D06GDY
D06VML
DB00715
DivK1c_006884
DR001531
DSSTox_CID_3425
DSSTox_GSID_23425
DSSTox_RID_77022
DTXSID3023425
FG 7051
FG-7051
Frosinor
FT-0085087
GTPL4790
HE295209
HMS2090H05
HSDB 7175
I14-7752
KB-277026
KB-302613
KBio1_001828
KBio2_002232
KBio2_004800
KBio2_007368
KBioSS_002232
KS-00000JK2
LS-114249
MolPort-003-849-791
Motivan
NCGC00025355-02
NCGC00025355-03
NCGC00025355-04
NCGC00025355-05
NCGC00025355-06
NCGC00025355-07
NCGC00025355-08
NCGC00025355-09
NCGC00025355-12
NCGC00182968-01
NNC-20-7051
Paroxetin HCL
Paroxetina
Paroxetina [INN-Spanish]
paroxetine
Paroxetine (TN)
Paroxetine (USP/INN)
Paroxetine [USAN:INN:BAN]
Paroxetine Hcl
PAROXETINE HCL HEMIHYDRATE
paroxetine hydrochloride (anhydrous or hemihydrate)
Paroxetine Hydrochloride Anhydrous
Paroxetine hydrochloride hemihydrate
Paroxetine hydrochloride hydrate
Paroxetine Mesilate
Paroxetine Mesylate
Paroxetine.HCl
Paroxetinum
Paroxetinum [INN-Latin]
Paxetil
Paxil
Paxil (TN)
Paxil, Pexeva
PaxPar
Pexeva
Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-
Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-
Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-
piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-
Piperidine,3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-
Piperidine,3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3S,4R)-
Prestwick3_000851
SBI-0051908.P002
SC-16100
SC-22977
SCHEMBL27799
Seroxat
Seroxat (TN)
Seroxat CR
SpecPlus_000788
Spectrum_001752
Spectrum5_001665
TL8003967
Tox21_113123
Tox21_113123_1
UNII-41VRH5220H
ZINC527386

US Patents and Regulatory Information for PAXIL CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-002 Feb 16, 1999 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-003 Dec 6, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for PAXIL CR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-003 Dec 6, 2000 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-003 Dec 6, 2000 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PAXIL CR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 37.5 mg ➤ Subscribe 2009-05-19
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2005-09-09

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Dow
Chubb
Cipla
Covington
Federal Trade Commission
Mallinckrodt
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.